• In early February 2026, a California federal jury found Medtronic liable for anticompetitive conduct in the advanced bipolar surgical devices market and ordered the company to pay more than US$381 million in damages to rival Applied Medical under U.S. and California antitrust laws.
• Beyond the large financial penalty, the verdict targets Medtronic’s contracting practices with hospitals and group purchasing organizations, potentially reshaping how its surgical devices compete for operating-room shelf space.
• We’ll now examine how this antitrust verdict and its focus on Medtronic’s hospital contracting practices could influence the company’s broader investment narrative.

Invest in the nuclear renaissance through our list of 87 elite nuclear energy infrastructure plays powering the global AI revolution.

What Is Medtronic's Investment Narrative?

For Medtronic, the big picture still revolves around owning a diversified, global medtech platform with solid earnings, reliable dividends and active buybacks, while accepting that growth is steady rather than spectacular. The new US$381 million antitrust verdict adds a legal and reputational wrinkle just as investors had been focusing on margin improvement, diabetes technology milestones and ongoing capital returns as the main near term catalysts. If the judgment stands and is followed by injunctive relief on contracting, it could pressure pricing power and share in certain surgical tools, and may prompt closer scrutiny of sales practices across the portfolio. At the same time, recent share price performance has not pointed to a sharp reset, suggesting the market is still weighing how material this risk is versus Medtronic’s cash generation and pipeline progress.

However, the antitrust verdict highlights a contracting risk that shareholders should not ignore. Despite retreating, Medtronic's shares might still be trading above their fair value and there could be some more downside. Discover how much.

Exploring Other Perspectives

Nine members of the Simply Wall St Community currently place Medtronic’s fair value between about US$95 and just under US$111, reflecting a tight but varied set of opinions. Against that backdrop, the new antitrust ruling and potential changes to hospital contracting add a layer of uncertainty that could shift how some investors think about Medtronic’s ability to convert its product milestones into sustained financial performance. This is an area where it helps to compare several viewpoints before forming a view.

Explore 9 other fair value estimates on Medtronic - why the stock might be worth as much as 9% more than the current price!

Build Your Own Medtronic Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Medtronic research is our analysis highlighting 5 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Medtronic research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Medtronic's overall financial health at a glance.

Looking For Alternative Opportunities?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• We've uncovered the 14 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Uncover the next big thing with 26 elite penny stocks that balance risk and reward.
• Explore 23 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.